Cellvizio 100 Series System with Confocal Miniprobes ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 215 | ファロー四徴症 | 1 |
215. ファロー四徴症
臨床試験数 : 22 / 薬物数 : 48 - (DrugBank : 19) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 49
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04017975 (ClinicalTrials.gov) | December 20, 2019 | 10/7/2019 | Optical Tissue Identification for Myocardial Architecture | Optical Tissue Identification for Myocardial Architecture (OPTIMA Study) | Ventricular Septal Defect;Complete Atrioventricular Canal;Tetralogy of Fallot With Pulmonary Stenosis | Drug: Fluorescite;Device: Cellvizio 100 Series System with Confocal Miniprobes | Aditya Kaza | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | N/A | 18 Years | All | 70 | Phase 2 | United States |